Investor Highlights


  • Investor Presentation - view here
  • Quarterly Shareholder Update - view here
  • Investment Summary - view here

Pharmaxis and Charlie Teo Foundation Identify Promising New Drug to Tackle Brain Cancer

Unique mechanism of drug action inhibits enzymes critical to tumour growth and survival

An Australian drug discovery will be the focus of a new study to tackle an aggressive and deadly form of brain cancer with a funding grant from the Charlie Teo Foundation. The drug, developed by Sydney-based research company Pharmaxis (ASX: PXS), will enter pre-clinical efficacy testing for glioblastoma (GBM), the most common form of brain cancer with an average survival of only 15 months from diagnosis.

Read full media release - pdf

Shareholder update - March 2021

Shareholder update for the quarter ended 31 March 2021

Read quarterly update - pdf

Pharmaxis Sells Bronchitol Russian Distribution Rights for A$2m with Annual A$1m Cost Savings


  • Pharmaxis sells distribution rights for Bronchitol in Russia effective May 1st 2021
  • Pharmaxis to receive a €1.25 million (~A$2m) distributor appointment fee
  • Annual cost savings of approximately A$1m realised from transfer of commercial and product responsibilities
Read full media release - pdf

Pharmaxis Announces World First Clinical Trial of Treatment to Prevent Wound and Burns Scars

A Pharmaxis (ASX:PXS) drug discovery has entered a world first clinical trial aiming to stop scars forming after trauma, particularly following burn injuries. Distinguished surgeon and burns expert Professor Fiona Wood AM is leading a group of researchers from the University of Western Australia (UWA) and Fiona Stanley Hospital to test the treatment in the first human trials. Skin scarring after events such as accidents, surgery or burns place a substantial physical and psychological burden on patients. 

Professor Fiona Wood said, “It’s exciting for the research team to explore a novel path to reduce scarring and to be moving closer to that goal. Scar-less healing is the vision that has motivated our work over many decades.”

The Pharmaxis discovery, known as PXS-6302, has shown promising pre-clinical results in inhibiting the enzymes that play a critical role in the development of scar tissue.

Dr Kylie Sandy-Hodgetts, Senior Research Fellow at the School of Biomedical Sciences, UWA, said, “Current treatments aim to rectify the scar in the acute phase such as during wound healing and scar maturation through options such as compression therapy, silicone gel sheeting or when the scar is established by cryotherapy, scar revision or laser with limited outcomes at times.”

“This new compound may potentially avoid the need for invasive procedures such as further surgery or laser procedures.”

 The world-first human trial will determine the safety and tolerability of the product in healthy volunteers, which will lead to further trials in burns and surgical patients.

Read full media release - pdf